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Optimizing media for perfusion 
combining predictive scale-down 
models and multivariate approaches
Medium Development
for Perfusion Processes
Perfusion medium development is complex and time-
consuming. Thus, a methodology for efficient and cost 
effective development leading to a significant reduction of 
time to market is key in today's competitive market. Success 
in perfusion medium development depends strongly on the 
choice of optimization tools. 
A typical procedure is described in Figure 1. Starting from a 
diverse panel of media, combined for the specific purpose, 
High-Throughput Systems (HTS) are applied to identify 
critical components, which are then optimized in 
concentration. Using the optimum raw materials allows for a 
soluble and stable cell culture media (CCM) formulation. 
Case Study: Optimization of 
Amino Acid Concentrations
The purpose of the study was to investigate the impact of 19 
amino acids on productivity and growth of a CHO K1 cell line 
in perfusion cell culture (SDM: unlimited growth SCP). 
Optimum amino acid concentrations were identified for cell 
growth and productivity based on a definitive screening 
design with three concentration levels (Jones & Nachtsheim, 
2011) followed by a classical central composite design (Box-
Wilson, 1951) for optimization (Figure 5).
Figure 6 shows the amino acids significantly correlated with 
maximum VCD, IVCD, titer and cell specific productivity (qP) 
in CCD results. As can be seen, some factor responses yield 
conflicting outcomes, as amino acids either improve growth 
or productivity, but not both.
Using these results, we designed two media: one using the 
optimum concentrations for growth (HiGrow), the other 
optimized for productivity (HiProd), and tested these media in 
4L perfusion bioreactors in unlimited growth conditions at 1 
vvd. Results are given in Figure 7.
We could confirm that the growth optimized medium provided 
higher VCD, and the production optimized medium had higher 
titer and productivity. However, the differences were smaller 
than the model, based on scale-down model results, had 
suggested. 
This approach provided an efficient way of screening a large 
number of conditions, thus accelerating development 
progress and reducing costs. These optimum conditions lead 
to significant improvements in productivity and cell growth at 
different scales.
For this case study, we would like to acknowledge the 
contribution of Pedro Felizardo and Jose Menezes (4tune 
Engineering) for Ch. Schultheiss’ MSc thesis!
EX-CELL® Advanced™ 
HD Perfusion Medium
Using a combination of the methods described above 
(Figures 1, 2, 3), we developed a perfusion specific catalog 
medium. During development, emphasis was on achieving 
maximum productivity and low CSPR to allow operating 
perfusion bioreactors at low perfusion rates (VVD). A wide 
array of CHO cell lines, producing monoclonal antibodies or 
fusion proteins, were used to ensure broad applicability.
In the following graphs, some examples are shown 
comparing EX-CELL® Advanced™ HD Perfusion medium with 
a blend of basal medium and feeds, which are sometimes 
used as quick fix to design a baseline perfusion medium. The 
first example is a CHOZN® GS cell line producing a 
monoclonal antibody (Figure 8).
The second example is a CHOZN® GS cell line producing a 
Fusion Protein. As these products tend to be more fragile, 
this is an excellent model product for perfusion.
Both examples indicate that significant improvement of 
productivity as well as reduction of CSPR could be achieved, 
compared to the basal/feed blend as well as some earlier 
prototypes.
EX-CELL® Advanced™ HD Perfusion medium (catalog no. 
24370C) is a chemically defined cell culture medium without 
glutamine as suitable for CHOZN® or other GS engineered 
cell lines. It was also tested for DHFR engineered cell lines 
successfully, adding Glutamine according to cellular 
requirements. It is highly concentrated and well-balanced to 
support high cell density perfusion (50e6 or higher). It is the 
first medium on the market specifically designed for high cell 
density perfusion, making it superior in terms of productivity 
(see Figures 8 and 9).
Figures 1, 2, 8 and 9 by courtesy of Delia Lyons, Jeremy 
Riesberg and Dustin Davis.
Summary
Perfusion medium development and optimization offers great 
performance increases for perfusion processes. We present 
several aspects of the capabilities we have developed recently 
to support both customized perfusion medium optimization as 
well as catalog products.
Critical aspects include a task specific medium panel to start 
development, various scale-down models (SDM) to achieve 
representative results during optimization in different phases 
of development, and multivariate tools to facilitate component 
optimization. Our example shows how media can be designed 
and optimized for different target outcomes.
Using these capabilities we developed the first-of-its-kind EX-
CELL® Advanced™ HD Perfusion medium, which allows for 
high cell density perfusion at lowest possible perfusion rates. 
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Figure 1: Integrated Medium Development Process
Scale-Down Models for 
Perfusion Development
The cultivation vessels typically used for perfusion are 
depicted in Figure 2.
For the miniaturized bioreactors, appropriate operating 
parameters have to be determined to achieve results 
representative for perfusion bioreactors. For example, 
SpinTube bioreactors can be operated in batch mode (RB), 
semi-continuous chemostat (SCC) or semi-continuous 
perfusion (SCP), giving different levels of precision as scale-
down models. The scaling criterion is cell specific perfusion 
rate (CSPR).
For steady-state operation, we refined the SCP model by a 
daily dilution step to provide constant average VCD (Figure 
4). This scale-down model is most useful for bioreactor 
process development, as it allows to parallelize “push-to-
low” experiments to determine minimum CSPR values for 
the medium-cell combination (Konstantinov, 2006).
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We found that SCP is a 
good model for 2L 
perfusion bioreactor 
performance in terms of 
growth, metabolism and, 
most importantly, specific 
productivity (qP) (Fig.3).
In our case study, we 
investigated both
unlimited growth (simple) 
as well as steady-state 
perfusion (more complex 
to operate).
Figure 2: Cultivation systems in medium development
Figure 3: Scale-Down Model (SDM) operating modes and qP 
results obtained with SDM compared to 2L bioreactors.
Figure 4: Steady-state operation in 
SpinTube. In this example, steady-state 
could only be obtained at CSPR of 0.020 
nL/cell.d or higher.
Figure 5: DoE experimental designs and MVDA steps for 
optimizing 19 amino acid concentrations.
Figure 6: Central Composite Design factor response of amino 
acid concentration and their impact on performance and 
desirability. Red numbers refer to optimum values predicted by 
the model.
Figure 7: Results of bioreactor confirmation with media 
optimized for growth (HiGrow) or productivity (HiProd).
Figure 8: Comparison of EX-CELL® Advanced™ HD Perfusion 
medium with a blend of basal medium and feeds for a CHOZN®
GS cell line producing a monoclonal antibody.
Figure 9: Comparison of EX-CELL® Advanced™ HD Perfusion 
medium with a blend of basal medium and feeds for a CHOZN®
GS cell line producing a Fusion Protein.
